| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6017927 | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
Nov, 2018
(5 years ago) | |
|
US6017927 (Pediatric) | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
May, 2019
(4 years ago) | |
Vesicare is owned by Astellas.
Vesicare contains Solifenacin Succinate.
Vesicare has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vesicare are:
- US6017927
- US6017927*PED
Vesicare was authorised for market use on 19 November, 2004.
Vesicare is available in tablet;oral dosage forms.
The generics of Vesicare are possible to be released after 19 May, 2019.
Drugs and Companies using SOLIFENACIN SUCCINATE ingredient
Market Authorisation Date: 19 November, 2004
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of VESICARE before it's drug patent expiration?
More Information on Dosage
VESICARE family patents
